I
ntracerebral hemorrhage (ICH) is a deadly form of stroke with mortality rates approaching 50%. 1 HMG-CoA reductase inhibitors (statins) induce several potential neuroprotective effects including an increase in cerebral perfusion, 2 activation of survival signals, 3 synthesis of heat shock protein 27, 4 and increases in angiogenesis and neurogenesis. 5 Indeed, statins were identified as modulators of lesion size and outcome in animal models of cerebral ischemia, 2 trauma, 6 and subarachnoid 7 and intracerebral hemorrhage. 8 Statins may protect the brain when administered shortly after injury but may also afford protective effects in patients taking statins for dyslipidemia before the injury. 9 Thus, for patients with acute ischemic stroke premorbid statin use was associated with smaller lesion volumes and better functional outcome. 10 However, effects of statins yielded conflicting results in humans with ICH. 11, 12 Therefore, we set out to investigate whether pre-ICH statin use results in better survival and outcome measures.
Methods
The National Acute Stroke Survey in Israel Study (NASIS) studies were prospective observational studies in which all patients with acute cerebrovascular disease admitted to any one of the 28 hospitals nationwide between February and March of 2003 (NASIS 2003) or March through April of 2007 (NASIS 2007) were included. 13 Both NASIS studies used similar methods and data retrieval sheets to collect pertinent demographic, clinical, radiological, and outcome measures, as previously detailed. 13 In this report we focus on patients with ICH, diagnosed on CT or MRI. Patients with hemorrhagic transformation of ischemic strokes and those with hemorrhage into tumors were excluded. Neurological deficits were determined with the National Institute of Health Stroke Scale score (NIHSSS) and handicap before and after the hospitalization using the modified Rankin scale (mRS). Because ICH is frequently deadly we considered a mRS score of 0 to 3 as good outcome. Because exact drug doses and length of treatment, LDL, and total cholesterol levels were not required for patients with ICH, these data were unavailable to us.
Statistical Methods
Differences in age-adjusted rates were compared using the CochranMantel-Haenszel 2 test. A propensity score estimating the likelihood of taking statins before ICH was calculated for each patient by logistic regression analysis that included 12 covariates. Multivariable logistic regressions were performed, adjusting for potential confounders and the propensity score of pre-ICH statin use stratified into tertiles.
Results
Among the 3212 stroke patients included in NASIS 2003 and 2007, 312 (9.7%) fulfilled entry criteria for ICH, with a mean age of 77.4Ϯ9.9 years. Eighty-nine (28.5%) patients were reportedly on chronic statin therapy at the time of ICH onset. The demographic and risk factor profile of the patients are presented in Table 1 .
At presentation to the hospital the neurological deficits were lower in patients that were on statins (Table 2) . Furthermore, during hospitalization infectious complication rates were significantly lower for patients on statins as were death rates. In contrast, the chances for good outcome and discharge home or to a rehabilitation facility were higher in patients on statins. Of note, while the percentages of patients with excellent outcome (mRS 0 to 1) were similar between the 2 groups, the percentage of patients with good outcome (mRS 2 to 3) was much higher in patients treated with statins. Conversely, the percentage of patients with poor outcome (mRS 4 to 5) or death was much higher in untreated patients.
Multivariable logistic regression analyses adjusting for the propensity to receive statins (Table 3) revealed that premorbid statin use resulted in an more than 50% lower chance for having severe neurological deficits on admission (OR 0.46, 95% CI 0.23 to 0.93), a 3-fold increase in the chances of having a good outcome (OR 2.97, 95% CI 1.25 to 7.35), and a 75% lower chance of discharge to a chronic care nursing home or death (OR 0.25, 95% CI 0.09 to 0.63).
Discussion
The main findings of the current study are that the use of statins before ICH was associated with lower neurological disability at onset and a shift from poor to good outcome. This is also supported by the findings that significantly more patients on statins were discharged either home or to a rehabilitation facility.
Previous reports demonstrated induction of apoptosis, inflammation, and excitotoxic cascades after ICH, 14 and statins may provide multi-faceted protective effects that could reduce such damage. 2,3,5 However, findings regarding the effects of statins in humans with ICH have been limited and inconclusive, with one study reporting protective effects 12 and another failing to find such effects. 11 Both studies were single-center retrospective analyses of data accrued over many years in contrast to the current prospective multi-center dataset. Furthermore, FitzMaurice and colleagues 11 used different definitions of good outcome (GOS 4 to 5) at 90 days, which may account for the difference between the studies. Importantly, in the prospective secondary prevention SPARCL study, 15 Atorvastatin treatment led to a slight increase in the frequency of cerebral hemorrhages. However, the study included only a few patients with ICH, and the exact effects of aggressive LDL lowering on the frequency of recurrent ICH remain unclear as previous studies failed to show an increase in the frequency of ICH. 11 Our study has several potential limitations. First, we recruited patients over 2 separate time windows in 2003 and 2007, but used similar methods and data acquisition forms. Second, because of the relatively small number of patients on statins before ICH we could not test whether any particular statin or dose had superior effects. Third, in this study we did not have raw imaging data that would enable us to control for radiological prognostic markers. Finally, this is an observational study rather than a randomized clinical trial, and it is possible that unmeasured or unknown confounders may have influenced the results. Multiple logistic regression models were, however, conducted with adjustment for the propensity to receive a statin before the ICH to reduce potential bias. Because of our limited statistical power and because our findings are novel, they should be regarded as hypothesis-generating and verified in other cohorts.
In conclusion, our study findings suggest that statins could have protective effects after ICH manifesting in reduced neurological deficits at presentation, lower death, and dependency rates and increased chances for good outcome. 
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